| abstract |
PROBLEM TO BE SOLVED: To provide a therapeutic immunoconjugate containing SN-38 bound to an antibody or an antigen-binding antibody fragment. A pharmaceutical composition for treating cancer containing an immunoconjugate containing SN-38 conjugated to an antibody or an antigen-binding fragment thereof, wherein the antibody is hL243 (anti-HLA-DR). , The immunoconjugate is used to be administered to a human subject with cancer at a dosage between 4 mg / kg and 16 mg / kg. [Effect] When administered at a prescribed dosage and schedule, the immunoconjugate can shrink the tumor in size, shrink or eliminate metastasis, and can be used in radiation therapy, chemotherapy, immunotherapy, etc. It is effective in treating cancer that is resistant to standard therapies. [Selection diagram] FIG. 8 |